Plenary 1: Innovations in liver disease therapy: present and future

  • Innovations in direct-acting antiviral therapies
  • Innovations in antiviral immunotherapy
  • Innovations in liver fibrosis and NASH therapy
  • Innovations in hepatocellular carcinoma therapy

Plenary 2: Public health interventions in liver diseases

  • Public health tools to eliminate viral hepatitis
  • Global achievements and failures in viral hepatitis elimination
  • HCV elimination in Egypt: a success story
  • Public health interventions to eliminate NAFLD/NASH

Plenary 3: New vaccine approaches for liver diseases

  • The story and future of RNA vaccines
  • Towards an HCV vaccine
  • The future of therapeutic vaccines for viral infections
  • Implementing global vaccination strategies

Plenary 4: Global Hepatitis Summit 2023 Debrief

  • HCV Debrief
  • HBV/HDV Debrief
  • NAFLD/NASH Debrief
  • HCC Debrief

Basic Parallel 1: HCV/flavivirus virology

  • What did HCV teach us on flavivirus virology
  • HCV entry: lessons learnt for other viruses

Basic Parallel 2: HCV immunology

  • Innate immune responses against HCV
  • Adaptive immune responses against HCV

Basic Parallel 3: HBV/HDV virology

  • Update on HBV virology
  • Update on HDV virology

Basic Parallel 4: HBV/HDV immunology

  • Immunological phenotyping of HBV infections
  • Liver compartmentalization of anti-HBV immune responses

Basic Parallel 5: HBV/HDV treatment targets

  • Targeting HBV capsids for therapy
  • Targeting HBV RNAs for therapy

Basic Parallel 6: NASH targets for new therapies

  • Molecular targets for NASH therapy
  • Preclinical assessment of NASH compounds

Basic Parallel 7: HCC targets for new therapies

  • Molecular targets for HCC therapy
  • Immunological targets for HCC therapy

Basic Parallel 8: HEV virology and persistence

  • Update on HEV virology
  • Mechanisms of HEV persistance in immunodepressed patients

Basic Parallel 9: Liver inflammation and fibrogenesis

  • Mechanisms of NAFLD/NASH-associated liver inflammation
  • Mechanisms of liver fibrogenesis

Clinical Parallel 1: Applications of artificial intelligence in liver disease management

  • Artificial intelligence for liver cancer management
  • Artificial intelligence for liver fibrosis management

Clinical Parallel 2: Difficult-to-treat HCV patients

  • Unusual HCV genotypes/subtypes
  • Difficult-to-cure HCV liver diseases

Clinical Parallel 3: New strategies with approved HBV treatments

  • Stoppings NUC strategies
  • Interferon add-on/switch strategies

Clinical Parallel 4: New HBV drug clinical developments

  • Direct-acting antiviral HBV drugs in development
  • Anti-HBV immunotherapies and combination perspectives

Clinical Parallel 5: New HDV therapies

  • Bulevirtide in HDV therapy
  • New treatments in HDV (except bulevirtide)

Clinical Parallel 6: Long-term outcomes of treated patients with viral hepatitis

  • Long-term outcomes of treated HBV patients
  • Long-term outcomes of cured HCV patients

Clinical Parallel 7: NAFLD/NASH therapeutic developments

  • Endpoints in NAFLD/NASH therapeutic developements
  • New treatment approaches for NAFLD/NASH

Clinical Parallel 8: Impacts of COVID-19 on liver disease management

  • Negative impacts of COVID-19 on liver disease management
  • Positive impacts of COVID-19 on liver disease management

Clinical Parallel 9: Hepatocellular carcinoma new drug clinical trials

  • HCC new drug clinical trials in Europe and North America
  • HCC new drug clinical trials in Asia

Clinical Parallel 10: Viral hepatitis and liver transplantation in 2023

  • HCV and liver transplantation: 2023 update
  • HBV/HDV and liver transplantation: 2023 update

Clinical Parallel 11: New biomarkers for liver diseases

  • New biomarkers for fibrosis assessment
  • New biomarkers for HCC risk prediction

Clinical Parallel 12: New developments in liver pathogen detection and discovery

  • Metagenomics for pathogen diagnosis and discovery
  • Acute severe hepatitis of unknown origin in children

PH Parallel 1: Epidemiology of HCV in resource-limited countries

  • Prevalence of HCV infection in resource-limited countries
  • Dynamics of the HCV epidemic in resource-limited countries

PH Parallel 2: Global epidemiology of HBV/HDV infections

  • Global epidemiology of HBV infection
  • Global epidemiology of HDV infection

PH Parallel 3: Viral hepatitis elimination achievements and challenges

  • Global viral hepatitis elimination achievements
  • Global viral hepatitis elimination challenges

PH Parallel 4: Simplified approaches for screening and diagnosis of viral hepatitis

  • Simplified approaches for HCV screening and diagnosis
  • Simplified approaches for HBV/HDV screening and diagnosis

PH Parallel 5: Reaching vulnerable populations for viral hepatitis elimination

  • Reaching PWID/prison populations for viral hepatitis elimination
  • Reaching migrant populations for viral hepatitis elimination

Late-Breaker

ANRS/AFEF: The French model

  • The French viral hepatitis program
  • The French HBV cure program

Debate Session 1: Public health

  • Post-COVID relaunch of HCV testing/treatment
  • Improving screening and linkage-to-care in viral hepatitis B and C
  • Public health interventions and awareness in NAFLD/NASH
  • Engaging policy makers and patient advocacy groups in liver disease

Debate Session 2: Clinical

  • Revisiting HBV treatment guidelines: a 2023 update
  • Understanding HBV biomarkers, redifining new treatment endpoints
  • The path forward in NAFLD/NASH therapeutic developments
  • Classification of HCC patients for therapy
WE’RE COUNTING DOWN THE DAYS UNTIL WE MEET AGAIN!
Days
Hours
Minutes
Seconds

REGISTER

before xxxx
and save up to xx

IMPORTANT DATES

Abstract submission opens

Early September 2022

Early bird registration opens

Mid September 2022

Abstract submission deadline

December 6, 2022

SIGN ME UP FOR UPDATES